接種新冠疫苗是保護自己和大家的唯一辦法。
只接種了一針或两針疫苗後，不論是那種疫苗，你仍然無法抵抗Omicron新冠肺炎變種病毒。染病而病徵輕微的你，更不自覺地把病毒散播。
所以必需接種第三針疫苗，最好是復必泰 mRNA疫苗。
衞生防護中心轄下科學委員會建議: 已接種兩劑克爾來福或復必泰疫苗的成年人於接種第二劑三個月後盡快接種第三劑復必泰疫苗。
祝大家身體健康，很快回歸正常生活。
以下圖表給大家參考:
混合新冠肺炎疫苗結果
Reply
Category Archives: COVID-19
肺炎疫苗比較
Moderna reported that during the phase 3 study of its vaccine candidate mRNA-1273, which enrolled 30,000 adult U.S. participants, just five of the 95 COVID-19 cases occurred among the vaccinated, while 90 infections were identified in the placebo group. This corresponds to an efficacy of 94.5%. None of the infected patients who received the vaccine developed severe COVID-19, while 11 (12%) of those who received the placebo did.
Similarly, the Pfizer-BioNTech vaccine candidate, BNT162b2, was 90% effective in preventing infection during the phase 3 clinical trial, which enrolled 43,538 participants, with 30% in U.S. and 42% abroad.